US Bancorp DE Sells 469 Shares of AtriCure, Inc. (NASDAQ:ATRC)

US Bancorp DE cut its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 32.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 997 shares of the medical device company’s stock after selling 469 shares during the period. US Bancorp DE’s holdings in AtriCure were worth $28,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ATRC. Comerica Bank raised its stake in shares of AtriCure by 70.5% during the first quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock worth $77,000 after buying an additional 1,043 shares during the last quarter. Quest Partners LLC grew its holdings in AtriCure by 38.3% during the 2nd quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock worth $134,000 after acquiring an additional 1,626 shares during the period. nVerses Capital LLC grew its holdings in AtriCure by 733.3% during the 3rd quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company’s stock worth $140,000 after acquiring an additional 4,400 shares during the period. Mount Yale Investment Advisors LLC raised its position in shares of AtriCure by 32.1% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company’s stock valued at $222,000 after acquiring an additional 2,368 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of AtriCure by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 8,371 shares of the medical device company’s stock valued at $255,000 after purchasing an additional 659 shares during the period. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Performance

Shares of ATRC opened at $34.72 on Tuesday. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -41.83 and a beta of 1.41. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.00. The firm has a fifty day simple moving average of $30.08 and a 200 day simple moving average of $25.43. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. The company had revenue of $115.91 million during the quarter, compared to the consensus estimate of $112.23 million. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The company’s quarterly revenue was up 17.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.20) EPS. Research analysts forecast that AtriCure, Inc. will post -0.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ATRC shares. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a research note on Saturday, September 14th. JPMorgan Chase & Co. upped their price target on AtriCure from $30.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Oppenheimer increased their price target on shares of AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Piper Sandler decreased their price target on shares of AtriCure from $65.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Finally, Needham & Company LLC increased their price target on AtriCure from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.11.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.